TOVX
Income statement / Annual
Last year (2024), Theriva Biologics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Theriva Biologics, Inc.'s net income was -$25.65 M.
See Theriva Biologics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$272.00 K
|
$245.00 K
|
$157.00 K
|
$72.00 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$272.00 K
|
-$245.00 K
|
-$157.00 K
|
-$72.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$12.03 M
|
$14.31 M
|
$11.72 M
|
$7.80 M
|
$5.13 M
|
$11.08 M
|
$11.84 M
|
$18.78 M
|
$29.11 M
|
$32.91 M
|
| General & Administrative Expenses |
$7.40 M
|
$7.16 M
|
$7.00 M
|
$6.47 M
|
$4.82 M
|
$4.38 M
|
$5.73 M
|
$7.47 M
|
$10.14 M
|
$8.07 M
|
| Selling & Marketing Expenses |
$0.00
|
$624.00 K
|
$569.00 K
|
$0.00
|
$209.00 K
|
$201.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$7.40 M
|
$7.78 M
|
$7.57 M
|
$6.47 M
|
$5.03 M
|
$4.58 M
|
$5.73 M
|
$7.47 M
|
$10.14 M
|
$8.07 M
|
| Other Expenses |
$6.92 M
|
-$660.00 K
|
$2.29 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$26.35 M
|
$21.43 M
|
$21.58 M
|
$14.27 M
|
$10.16 M
|
$15.66 M
|
$17.57 M
|
$26.25 M
|
$39.25 M
|
$40.98 M
|
| Cost And Expenses |
$26.35 M
|
$21.43 M
|
$21.58 M
|
$14.27 M
|
$10.16 M
|
$15.66 M
|
$17.57 M
|
$26.25 M
|
$39.25 M
|
$40.98 M
|
| Interest Income |
$697.00 K
|
$1.44 M
|
$512.00 K
|
$6.00 K
|
$44.00 K
|
$283.00 K
|
$67.00 K
|
$21.00 K
|
$37.00 K
|
$6.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$137.00 K
|
$135.00 K
|
$85.00 K
|
$87.00 K
|
$201.00 K
|
$240.00 K
|
$272.00 K
|
$245.00 K
|
$157.00 K
|
$72.00 K
|
| EBITDA |
-$19.29 M |
-$21.96 M |
-$19.21 M |
-$14.19 M |
-$9.96 M |
-$15.42 M |
-$17.30 M |
-$26.01 M |
-$39.10 M |
-$40.91 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$693.00 K
|
$1.44 M
|
$471.00 K
|
$6.00 K
|
$44.00 K
|
$283.00 K
|
$4.15 M
|
$10.76 M
|
$11.45 M
|
-$3.81 M
|
| Income Before Tax |
-$25.65 M
|
-$19.99 M
|
-$21.11 M
|
-$14.27 M
|
-$10.12 M
|
-$15.38 M
|
-$13.42 M
|
-$15.49 M
|
-$27.80 M
|
-$44.79 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
-$1.64 M
|
-$1.43 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$25.65 M
|
-$18.35 M
|
-$19.69 M
|
-$14.27 M
|
-$10.04 M
|
-$15.30 M
|
-$13.37 M
|
-$15.17 M
|
-$27.26 M
|
-$43.74 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-19.03 |
-28.49 |
-32.66 |
-1.9 |
-6.6 |
-9.14 |
-21.45 |
-42.7 |
-101.17 |
-189.68 |
| EPS Diluted |
-19.03 |
-28.48 |
-32.66 |
-1.9 |
-6.6 |
-9.14 |
-21.45 |
-42.7 |
-101.17 |
-189.68 |
| Weighted Average Shares Out |
$1.35 M
|
$644.00 K
|
$613.09 K
|
$12.19 M
|
$1.90 M
|
$1.64 M
|
$623.24 K
|
$355.33 K
|
$269.40 K
|
$230.58 K
|
| Weighted Average Shares Out Diluted |
$1.35 M
|
$644.28 K
|
$613.09 K
|
$12.19 M
|
$1.90 M
|
$1.64 M
|
$623.24 K
|
$355.33 K
|
$269.40 K
|
$230.58 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
